Person:
BUĞDAYCI, ONUR

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

BUĞDAYCI

First Name

ONUR

Name

Search Results

Now showing 1 - 10 of 51
  • Publication
    Radyolojik değerlendirmede genel prensipler
    (2018-04-22) BUĞDAYCI, ONUR; BUĞDAYCI O.
  • Publication
    Neoadjuvan kemoterapi uygulanan meme kanserli olgularda güvenli tümör-meme ucu mesafesini meme MR öngörebilir mi?
    (2022-02-24) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; BUĞDAYCI, ONUR; KAYA, HANDAN; AKOĞLU, HALDUN; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., BUĞDAYCI O., KAYA H., AKIN TELLİ T., AKOĞLU H., GÜLLÜOĞLU M. B.
  • Publication
    Venous thrombosis in a pseudohypoparathyroidism patient with a novel GNAS frameshift mutation and complete resolution of vascular calcifications with acetazolamide treatment
    (2023-01-01) TRUE, ÖMER; BUĞDAYCI, ONUR; GÜRAN, TÜLAY; BEREKET, ABDULLAH; Menevse T. S., Iwasaki Y., Abali Z. Y., Tosun B. G., Helvacioglu D., DOĞRU Ö., BUĞDAYCI O., Cyr S. M., GÜRAN T., BEREKET A., et al.
    Introduction: Pseudohypoparathyroidism type IA (PHP1A) is characterized by end-organ resistance to multiple hormones and Albright’s hereditary osteodystrophy (AHO). PHP1A is caused by inactivating mutations of the GNAS gene encoding the α-subunit of the stimulatory G protein (Gsα). In line with the underlying genetic defect, impaired inhibition of platelet aggregation has been demonstrated in some patients. However, no PHP1A case with thrombotic events has been described. Also, PHP1A cases typically have subcutaneous ossifications, but soft tissue calcifications are another common finding. Treatment options for those and other nonhormonal features of PHP1A are limited. Case Presentation: A female patient presented with short stature, fatigue, and exercise-induced carpopedal spasms at age 117/12 years. Diagnosis of PHP1A was made based on hypocalcemia, hyperphosphatemia, elevated serum parathyroid hormone, and AHO features, including short stature and brachydactyly. A novel frameshift variant was detected in the last exon of GNAS (c.1065_1068delGCGT, p.R356Tfs*47), showing complete loss of baseline and receptor-stimulated activity in transfected cells. The patient developed venous thrombosis and vascular and subcutaneous calcifications on both forearms after venous puncture on the right and extravasation of calcium gluconate during treatment on the left. The thrombosis and calcifications completely resolved following treatment with low-molecular-weight heparin and acetazolamide for 5 and 8 months, respectively. Conclusions: This case represents the first PHP1A patient displaying thrombosis and the first successful use of acetazolamide for PHP1A-associated soft tissue calcifications, thus providing new insights into the treatment of non-endocrinological features in this disease.
  • Publication
    Oyun Değiştiren Güç: Yapay Zekâ.
    (Beta Basım Yayım Dağıtım, 2020-06-01) AKYURT, NURAN; OKTAR, FAİK NÜZHET; ACAR BÜYÜKPEHLİVAN, GÜLHAN; BUĞDAYCI, ONUR; Akyurt N., Oktar F. N. , Acar Büyükpehlivan G., Buğdaycı O.
  • Publication
    Breast ultrasonography: How useful in the diagnosis of precocious puberty?
    (2022-09-15) BIYIKLI, ERHAN; BUĞDAYCI, ONUR; DEMİRCİOĞLU, SERAP; GÜRAN, TÜLAY; BEREKET, ABDULLAH; HELVACIOĞLU D., BIYIKLI E., BUĞDAYCI O., DEMİRCİOĞLU S., GÜRAN T., BEREKET A.
  • Publication
    Meme kanserinde neoadjuvan kemoterapi sonrası es-zamani: Rekonstrüksiyon güvenli midir? 5 yıllık tek merkez onkolojik sonuçlar
    (2022-09-18) UĞURLU, MUSTAFA ÜMİT; AKMERCAN, AHMET; SAÇAK, BÜLENT; AKDENİZ DOĞAN, ZEYNEP DENİZ; KAYA, HANDAN; BUĞDAYCI, ONUR; GÜLLÜOĞLU, MAHMUT BAHADIR; UĞURLU M. Ü., AKMERCAN A., SAÇAK B., AKDENİZ DOĞAN Z. D., HAYTAOĞLU A. A., KAYA H., BUĞDAYCI O., AKIN TELLİ T., ÖZGEN Z., GÜLLÜOĞLU M. B.
  • Publication
    Nodüler tiroid hastalıklarında USG ve renkli doppler USG bulgularının histopatolojik ve sitolojik bulgularla korelasyonu
    (2006-09-10) BUĞDAYCI, ONUR; GÜLLÜOĞLU, MAHMUT BAHADIR; AHISKALI, ASİYE RENGİN; ASLAN A., SANCAK S., aslan m., BUĞDAYCI O., GÜLLÜOĞLU M. B. , AHISKALI A. R. , akalın s., arıbal e.
  • Publication
    Restoration of Height after 11 Years of Letrozole Treatment in 11 beta-Hydroxylase Deficiency
    (KARGER, 2020) BEREKET, ABDULLAH; Atay, Zeynep; Turan, Serap; Bugdayci, Onur; Guran, Tulay; Bereket, Abdullah
    11 beta-hydroxylase deficiency (11 beta-OHD) is the second most common form of congenital adrenal hyperplasia (CAH). Males with 11 beta-OHD CAH are often diagnosed late with a significantly advanced bone age leading to a poor height prognosis due to early closure of epiphysis. Delaying epiphyseal fusion by treatment of aromatase inhibitors (AIs) might be a useful strategy in patients with very advanced bone ages. However, there are limited data regarding the effect on final height and long-term safety of this approach. We report our experience with 11 years of letrozole treatment and 17 years of follow-up in a boy with 11 beta-OHD. He presented at 2 years and 11 months of age with a bone age of 13 years (predicted adult height, PAH, 129.5 cm). Letrozole was added after 1 year of glucocorticoid treatment due to no improvement in height prognosis (130 cm), and continued until the age of 14 years and 11 months. He also received GnRH analog treatment at 10 years and 3 months of age for 2.5 years due to central activation of puberty. He reached a final height of 165.2 cm (35.2 cm above his PAH). This long-term treatment with letrozole was associated with changes in vertebral morphology such as vertebral body end-plate changes, Schmorl nodes, and mild protrusions in the intervertebral discs. Testicular volumes, gonadotropins, testosterone, and anti-Mullerian hormone were normal at age 20 years. A spermiogram showed a normal count but impaired sperm motility and morphology. This unique case represents the longest duration of AI treatment reported in CAH and the first case in which letrozole was started before puberty with the final height reported. We conclude that AIs may restore height in selected patients with CAH with very advanced bone age and severely compromised height prognosis.
  • Publication
    Malign benign ayrımında görüntüleme - USG ne görür
    (2022-01-09) BUĞDAYCI, ONUR; BUĞDAYCI O.
  • Publication
    Hpr prevalence of inflammatory back pain in primary sjogren’s syndrome is increased and associated with acute and structural changes of the sacroiliac joint
    (2023-06-15) BIYIKLI, ERHAN; BUĞDAYCI, ONUR; ATAGÜNDÜZ, MEHMET PAMİR; ABACAR K. Y., ÇOLAKOĞLU ÖZKAYA Ş., BIYIKLI E., BUĞDAYCI O., ATAGÜNDÜZ M. P., SELÇUK Z. D.